Welcome to our dedicated page for Hamilton Lane news (Ticker: HLNE), a resource for investors and traders seeking the latest updates and insights on Hamilton Lane stock.
Hamilton Lane Incorporated (Nasdaq: HLNE) is a prominent global private markets investment management firm. With a history spanning over three decades, Hamilton Lane has become a cornerstone in the private investment landscape. The firm is dedicated to providing innovative investment solutions to institutional and private wealth investors worldwide. As of December 31, 2023, the firm oversees approximately $903 billion in assets under management and supervision, with $120 billion in discretionary assets and nearly $783 billion in non-discretionary assets.
Headquartered in Conshohocken, Pennsylvania, Hamilton Lane operates from offices across North America, Europe, Asia Pacific, and the Middle East, employing nearly 700 professionals. These offices include significant presences in major financial hubs such as New York, London, Hong Kong, Rio de Janeiro, Tel Aviv, and Tokyo.
Hamilton Lane provides a diversified array of private market investment products and services, encompassing private equity, private credit, real estate, infrastructure, natural resources, growth equity, venture capital, and impact investments. Their expertise extends to building flexible investment programs that enable clients to access the full spectrum of private market strategies, sectors, and geographies.
The firm generates revenue primarily through management and advisory fees, reflecting its role in managing and supervising client portfolios. This broad and customized client service includes conceiving, structuring, building, managing, and monitoring portfolios of private market funds and direct investments.
Recent Developments:
- March 4, 2024: Hamilton Lane announced pricing of an underwritten public offering of 1,922,322 shares of Class A common stock, generating gross proceeds of approximately $210 million.
- March 7, 2024: Hamilton Lane released its annual Market Overview, offering a comprehensive data-driven analysis of the private markets.
- April 10, 2024: Hamilton Lane expanded its Canadian operations with a larger office in Toronto, reflecting continued growth in the region.
- May 1, 2024: Hamilton Lane participated in a $47 million funding round for Securitize, a leader in tokenizing real-world assets.
- May 23, 2024: Hamilton Lane reported strong financial results for the fiscal year ending March 31, 2024, continuing its trend of robust growth and performance.
For more information about Hamilton Lane, please visit their official website at www.hamiltonlane.com.
Cosette Pharmaceuticals has announced a definitive agreement to acquire Mayne Pharma Group for approximately USD $430 Million at AUD$7.40 per share. The transaction is expected to close in Q2 2025.
The acquisition will transform Cosette into a leading player in women's health and dermatology in the U.S., combining Cosette's 350+ strong team with Mayne Pharma's 480+ workforce. The merged entity will operate two FDA-approved manufacturing facilities in Lincolnton, North Carolina and Salisbury, South Australia.
Post-acquisition, Cosette will market 12 patent-protected products including notable brands such as VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® and RHOFADE®. The transaction has received approval from both companies' Boards of Directors, with Mayne Pharma's Board unanimously recommending shareholders vote in favor.
73 Strings has secured a $55 million Series B funding round led by Growth Equity at Goldman Sachs Alternatives, with participation from Blackstone Innovations Investments, Golub Capital, Hamilton Lane (HLNE), and Broadhaven Ventures. The company, which provides AI-powered data extraction, monitoring, and valuation solutions for the $17.6 Trillion AUM Alternative Asset Management space, will use the funds to accelerate product development and innovation.
The platform serves clients managing nearly $10 trillion in assets, enabling faster and more frequent valuations with enhanced transparency. The company plans to expand its capabilities through: building smarter systems with LLMs, implementing benchmarking & predictive analytics, introducing portfolio simulation features, and launching advanced dashboards specifically designed for private capital data.
PSG, a growth equity firm focused on software and technology-enabled services, has announced the closure of two funds totaling $8 billion in capital commitments. The firm's sixth North American flagship fund, PSG VI, closed at $6 billion, exceeding its predecessor fund of $4.7 billion. Additionally, PSG closed a $2 billion continuation fund, PSG Sequel, backed by major institutional investors including CPP Investments, GIC, StepStone, and Hamilton Lane.
PSG Sequel will maintain stakes in six portfolio companies: Arcoro, LivTech, Nextlane, Semarchy, Singlewire Software, and Transit Technologies. The firm, founded in 2014, has grown to manage over $28 billion in assets, with 269 professionals including 160 investment professionals. PSG has executed 75 realization events and expanded globally with offices in Boston, London, Kansas City, Paris, Madrid, and Tel Aviv. The firm has invested in 19 AI-driven companies and continues to leverage AI across its portfolio.
Hamilton Lane (Nasdaq: HLNE) has announced the pricing of a public offering of 1,572,536 shares of Class A common stock, with expected gross proceeds of approximately $252 million. The offering, which includes shares from both Hamilton Lane and a selling stockholder, is expected to close on February 12, 2025.
The company plans to use its portion of the proceeds to settle cash exchanges of membership units in Hamilton Lane Advisors, L.L.C. held by certain members. Hamilton Lane will not receive any proceeds from the selling stockholder's share sale. Morgan Stanley is serving as the book-running manager and underwriter for the offering, which is being conducted under an effective shelf registration statement filed with the SEC.
Hamilton Lane (Nasdaq: HLNE) has announced an underwritten public offering of 1,572,536 shares of Class A common stock, to be sold by both the company and a selling stockholder. The private markets asset management firm plans to use its portion of the proceeds to settle cash exchanges of membership units in Hamilton Lane Advisors held by certain members. The company will not receive any proceeds from the selling stockholder's share sale.
Morgan Stanley is serving as the book-running manager and underwriter for the offering. The offering is being conducted under an effective shelf registration statement (Registration No. 333-283233) filed with the SEC.
Cosette Pharmaceuticals has appointed Vincent Colicchio as Senior Vice President of Operations, effective February 3, 2025. Colicchio brings over 35 years of experience in pharmaceutical manufacturing and supply chain operations. Most recently, he served as Vice President of Supply Chain and External Manufacturing at Dr. Reddy's Laboratories, where he managed operations across North America and oversaw a network of more than 45 CMOs and CPOs.
In his previous role, Colicchio played a key role in acquiring and integrating Mayne Pharma's generics portfolio. His experience includes senior leadership positions at Amneal Pharmaceuticals, G&W Laboratories, GlaxoSmithKline, UCB Pharma, and Wyeth. At Cosette, he will lead manufacturing, global supply chain, and operational strategy to support the company's growth and transformation initiatives.
Hamilton Lane (Nasdaq: HLNE) announced the final close of its inaugural Venture Access Fund (VAF), raising $615.3 million in commitments, exceeding its $500 million target by 23%. The Fund targets top-performing, oversubscribed venture funds and companies, combining primary and secondary transactions to accelerate capital returns and mitigate the J-curve.
The fundraise attracted diverse global investors, including public and corporate pension funds, financial institutions, Taft-Hartley plans, family offices, and foundations. The Fund leverages Hamilton Lane's nearly 30-year venture investing experience and $117 billion in AUM and AUA across venture and growth equity.
The firm sees compelling opportunities in the current VC market, driven by AI and disruptive technologies, along with robust secondary market opportunities as companies stay private longer.
Hamilton Lane (HLNE) reported strong Q3 fiscal 2025 results, with total assets under management reaching $134.7 billion, representing a 12% year-over-year increase. The company's fee-earning assets grew by $7.9 billion to $71.0 billion.
Management and advisory fees rose 11% compared to the prior year period, reaching $126.3 million. The company's unrealized carried interest balance increased by 15% year-over-year to $1.3 billion. GAAP earnings per share stood at $1.32, with net income of $53.0 million for the quarter.
The company declared a quarterly dividend of $0.49 per share, targeting a full-year dividend of $1.96, marking a 10% increase from the previous fiscal year. Hamilton Lane's total assets under management and supervision reached $956.0 billion, comprising $134.7 billion in discretionary assets and $821.2 billion in non-discretionary assets.
Cosette Pharmaceuticals has appointed Brad Leonard as Vice President of Generics Commercial Operations to drive its next growth phase. Leonard will lead the company's generics business, including Sales, Marketing/Pricing, Customer Service, and Demand Planning. With over 30 years of pharmaceutical industry experience, Leonard previously contributed to Upsher-Smith Laboratories' success, earning multiple HDMA Diana Awards for product excellence and company performance.
President and CEO Apurva Saraf highlighted Leonard's deep industry expertise and track record in driving commercial success and strategic partnerships. Leonard, who holds a B.S. in Business Administration & Management from the University of Minnesota, expressed enthusiasm about joining Cosette during its period of accelerated growth and portfolio expansion.
Hamilton Lane's recent survey reveals a significant shift in private market investment trends, with 30% of investment advisors planning to allocate 20% or more to private markets in 2025, and another 29% planning 10%+ allocations. This represents a 15% increase from 2024.
Private infrastructure shows particular promise, with 48% of respondents planning to increase exposure, attracted by features like high barriers to entry, durable cash flows, and portfolio diversification. Private equity and credit remain top allocation choices.
The survey highlights that 76% of respondents view private markets as offering higher rewards compared to traditional investments, primarily driven by performance and diversification benefits. While 63% of advisors rate their private markets knowledge as 'advanced' (up from 55% last year), a knowledge gap persists.
Interest varies by generation, with highest engagement from Gen X (94%) and Millennials (89%). Geographically, Asia Pacific (51%) and the Americas (48%) show the strongest interest in private market investments.
FAQ
What is the current stock price of Hamilton Lane (HLNE)?
What is the market cap of Hamilton Lane (HLNE)?
What are the primary services offered by Hamilton Lane?
How large is Hamilton Lane's asset base?
Where is Hamilton Lane headquartered?
What recent milestones has Hamilton Lane achieved?
Who are Hamilton Lane's typical clients?
How does Hamilton Lane generate revenue?
In which regions does Hamilton Lane operate?
What is the significance of Hamilton Lane's Market Overview?
What was the purpose of Hamilton Lane's recent public stock offering?
Where can I find more information about Hamilton Lane?
